Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIT-2763 in Transfusion-Dependent Beta-Thalassemia
NCT04938635Phase 2Withdrawn
- Sponsor
- CSL Vifor
- Start
- Sep 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of vamifeport in beta thalassemia, sponsored by CSL Vifor. Planned start Sep 2021; status: withdrawn.
02
Drugs
vamifeport
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT04938635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938635.